key: cord-0820842-wqj0geud authors: Puga Gomez, R.; Ricardo Delgado, Y.; Rojas Iriarte, C.; Cespedes Henriquez, L.; Bello, M. P.; Vega Mendoza, D. L.; Pestana Perez, N.; Paredes-Moreno, B.; Rodriguez Gonzalez, M.; Valenzuela-Silva, C.; Sanchez-Ramirez, B.; Rodriguez-Noda, L.; Perez Nicado, R.; Gonzalez-Mugica, R.; Hernandez-Garcia, T.; Fundora-Barrios, T.; Dubet Echevarria, M.; Enriquez-Puertas, J. M.; Infante Hernandez, Y.; Palenzuela-Diaz, A.; Gato Orozco, E.; Chappi-Estevez, Y.; Francisco-Perez, J. C.; Suarez Martinez, M.; Castillo-Quintana, I. C.; Fernandez-Castillo, S.; Climent-Ruiz, Y.; Santana-Mederos, D. title: Open label phase I/II clinical trial and predicted efficacy of SARS-CoV-2 RBD protein vaccines SOBERANA 02 and SOBERANA Plus in children date: 2022-03-06 journal: nan DOI: 10.1101/2022.03.03.22271313 sha: f7a490e17f237e46850f189a08d6253fd1c2f33a doc_id: 820842 cord_uid: wqj0geud Objectives: To evaluate heterologous scheme in children 3-18 y/o using two SARS-CoV-2 r-RBD protein vaccines. Methods: A phase I/II open-label, adaptive and multicenter trial evaluated the safety and immunogenicity of two doses of SOBERANA02 and a heterologous third dose of SOBERANA Plus in 350 children 3-18 y/o in Havana Cuba. Primary outcomes were safety (in phase I) and safety/immunogenicity (in phase II) measured by anti-RBD IgG ELISA, molecular and live-virus neutralization tests and specific T-cells response. An immunobridging and prediction of efficacy were additional analysis. Results: Local pain was the unique adverse event with >10% frequency, none was serious or severe. Two doses of SOBERANA 02 elicited humoral immune response similar to natural infection; the third dose increased significantly the response in all children, similar to that achieved in vaccinated young adults and higher than in convalescents children. The neutralizing titer was evaluated in a participants subset: all had neutralizing antibodies vs. alpha and delta; 97.9% vs. beta. GMT was 173.8 (CI 95% 131.7; 229.5) vs. alpha, 142 (CI 95% 101.3; 198.9) vs. delta and 24.8 (CI 95% 16.8; 36.6) vs. beta. An efficacy over 90% was estimated. Conclusion: Heterologous scheme was safe and immunogenic in children 3-18 y/o. Trial registry: https://rpcec.sld.cu/trials/RPCEC00000374 Study design 99 We designed a phase I/II study, open-label, adaptive and multicenter to evaluate the safety, Phase I was conceived as a two-step, incorporating firstly 25 children 12-18 y/o (sequence 1). 105 The first interim report (no serious AE) seven days after vaccinated these children allowed The trial was conducted according to Helsinki's Declaration, Good Clinical Practice and the Spearman´s rank correlation was used to assess relationships among techniques used to evaluate 219 the immune response. ROC curve was used to choose the most appropriate cut-off for humoral 220 tests regarding the cVNT50. The Student t-Test or the Wilcoxon Signed-Rank Test were used 221 for before-after statistical comparison. A stopping criterion due to unacceptable toxicity (frequency >1%) was evaluated iteratively, 223 with a Bayesian algorithm. As an additional analysis, a non-inferiority of the immune response 224 in 3-11 and 12-18 y/o participants compared with that in 19-39 y/o participants (from not 225 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 6, 2022. Phase II: 150 aged 3-11 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 6, 2022. ; https://doi.org/10.1101/2022.03.03.22271313 doi: medRxiv preprint with vaccination (Table 3, Supplemental Material V-Table S2 ). AEs were more frequent after . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 6, 2022. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 6, 2022. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 6, 2022. ; https://doi.org/10.1101/2022.03.03.22271313 doi: medRxiv preprint higher among the youngers (3-11 y/o) after the second dose, but were similar in both age 335 subgroups after the third dose. The mVNT50 of antibodies was higher after both two and 336 three doses than after natural infection (Table 4) . (Table 5) . There was a good correlation among all humoral immunological variables, with coefficients 350 greater than 0.7 (Supplemental Material VI- Table S6 ). Predictive cut-off for attaining cVNT50 351 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Figure 2 ). An immunobridging analysis was performed for anti-RBD 372 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 6, 2022. ; https://doi.org/10.1101/2022.03.03.22271313 doi: medRxiv preprint 1.08 (0.68; 1.73) GMT and two-sided 95% confidence intervals were calculated by exponentiating the mean logarithm of the titers and the corresponding confidence intervals (based on the Student's t distribution). The geometric mean ratio and two-sided 95% confidence intervals were calculated by exponentiating the mean difference of the logarithms of the titers (in child/adolescents cohorts minus the 19-39-year-old cohort) and the corresponding confidence intervals (based on the Student's t distribution). The noninferiority criterion was met, since the lower boundary of the two-sided confidence interval for the geometric mean ratio was greater than 0.67. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted March 6, 2022. ; https://doi.org/10.1101/2022.03.03.22271313 doi: medRxiv preprint SARS-CoV-2 571 variants and ending the COVID-19 pandemic Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents Safety, tolerability, and 577 immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy 578 children and adolescents: A double-blind, randomised, controlled, phase 1/2 clinical 579 trial Carbohydrate-based vaccines: challenges and opportunities Phase I-II 584 study, sequential during phase I, open-label, adaptive and multicenter to evaluate the 585 safety, reactogenicity and immunogenicity of a heterologous two-dose schedule of the 586 prophylactic anti-SARS-CoV-2 vaccine candidate, FINLAY-FR-2 and a dose of 587 FINLAY-FR-1A Phase 1-2 Trial of a 590 SARS-CoV-2 Recombinant Spike Protein Nanoparticle Neutralizing 593 antibody levels are highly predictive of immune protection from symptomatic SARS-594 CoV-2 infection Effect of CMV and Aging on the Differential Expression of CD300a Symptomatic 601 acute myocarditis in 7 adolescents after Pfizer-BioNTech COVID-19 vaccination International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity Myocarditis cases 604 reported after mRNA-Based COVID-19 vaccination in the US from Vaccination against SARS-CoV-2 should be included in 607 childhood vaccination programs Las vacunas cubanas generan anticuerpos ante ómicron: Ese éxito 610 no puede llevarnos a la confianza Virus slams Cuba as it races to roll out its new vaccines The Role of the Thymus in the Immune Response Efficacy and Safety of 619 SOBERANA 02, a COVID-19 conjugate vaccine in heterologous three doses 620 combination Safety and immunogenicity of anti-623 SARS CoV-2 conjugate vaccine SOBERANA 02 in a two-dose or three-dose 624 heterologous scheme in adults: Phase IIb Clinical Trial Safety and immunogenicity of anti-628 SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme Molecular Aspects Concerning the Use of the SARS-CoV-2 Receptor Binding 632 Domain as a Target for Preventive Vaccines Immunosenescence in aging: 639 between immune cells depletion and cytokines up-regulation A synthetic conjugate polysaccharide vaccine against 643 Haemophilus influenzae type b Advisory Committee on Immunization Practices' interim recommendation for use of 647 COVID-19 vaccine in adolescents aged 12-15 years-United States Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age WHO COVID-19 -Landscape of novel coronavirus candidate vaccine development 654 worldwide World Health Organization. Causality Assessment of an Adverse Event Following 657 Immunization (AEFI) Safety and 661 immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people 662 younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial